Drug Profile
Aripiprazole/sertraline - Otsuka Pharmaceutical
Alternative Names: ASC-01; Sertraline/aripiprazoleLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Otsuka Pharmaceutical
- Class Amines; Antidepressants; Chlorobenzenes; Mood stabilisers; Naphthalenes; Piperazines; Quinolines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine D2 receptor agonists; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Major depressive disorder
Most Recent Events
- 30 Sep 2018 Discontinued - Phase-III for Major depressive disorder in Taiwan, South Korea, Malaysia, Australia (PO) (Otsuka Pharmaceutical pipeline, September 2018)
- 30 Sep 2018 Regulatory submission withdrawn for Major depressive disorder in Japan (PO) (Otsuka Pharmaceutical pipeline, September 2018)
- 27 Aug 2018 Otsuka Pharmaceutical completes a phase I bioequivalence trial in healthy volunteers in Japan (PO) (JapicCTI173774) (NCT03342963)